GSK plc
$163.76B- Market cap
- $107.65B
- Debt
- +$44.87B
- Cash
- −$3.40B
Capital structure 71% equity / 29% debt · EV / Revenue 3.71x · EV / EBITDA 19.25x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $107.65B · View financials
Snapshot Sep 4, 4:00 PM ET
FY 2025 · Mkt cap
Decision snapshot: GSK stock price at premium vs ARR $49.89 current versus $18.92 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ARR's multiple
Implied fair value · at GSK's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Higher is better
Pricing power
Operating leverage
Lower is better
Lower is better
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: GSK FY 2025 (ended Dec 31, 2025) · ARR FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 71% equity / 29% debt · EV / Revenue 3.71x · EV / EBITDA 19.25x
Capital structure 11% equity / 89% debt · EV / EBITDA 5.98x
GSK carries the larger enterprise value at $163.76B against $6.33B; ARR trades on the lower EV / EBITDA multiple (5.98x vs 19.25x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
GSK plc · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
ARMOUR Residential REIT, Inc. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
—
8.28x
Net debt / EBITDA
Leverage against operating earnings
6.59x
3.79x
Cash and equivalents
Liquid reserves on the balance sheet
$3.40B
$14.71B
Total debt
Interest-bearing obligations outstanding
$44.87B
$18.72B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.